Quantum capacitance induced by electron orbital reconstruction of g-C3N4/Co3O4 heterojunction: Improving electrochemical performance.

Utilizing diverse material combinations in heterogeneous structures has become an effective approach for regulating interface characteristics and electronic structures. The g-C3N4/Co3O4 heterostructures were fabricated by uniformly modifying Co3O4 nanoparticles onto discrete clusters of g-C3N4 nanosheets. Then, they were subsequently employed as positive electrode materials for assembling hybrid supercapacitors. According to the first-principles calculation, Co3O4 and g-C3N4 formed Co-N ionic bonds, establishing interfacial space symmetry-broken heterojunction and direct exchange and superexchange between ions at the interface and sub-interface. This resulted in a high-density spin-orbit hybrid heterogeneous polarization interface, significantly improving the quantum capacitance of heterojunction materials. Experimental results showed that the heterojunction had a specific capacitance of 2662 F g-1 at 1 A g-1. When the power density was 750 W kg-1, the energy density reached 128 Wh kg-1. Even when the power density was 16850 W kg-1, it could show an energy density of 62.5 Wh kg-1. The g-C3N4/Co3O4 heterojunction could realize high energy density charge storage as the cathode material of supercapacitors. The construction of heterogeneous polarization interfaces for high-energy quantum capacitors provides a new and effective method for the energy storage field.

[Long-term therapeutic effect of Zenapax after renal transplantation].

OBJECTIVE: To determine whether there was any lingering effect after discontinuing Zenapax in renal transplantation and investigate there was any alternative immunity-regulating pathway of Zenapax other than IL-2/IL-2R. METHODS: Thirty patients of renal transplantation were divided into 2 groups. One group of 15 received 2 dosages of induction therapy of Zenapax and another 15 regular immunosuppressive therapy. IL-2, IL-10, STAT5 and CD40L were tested followed up at 2 hours pre-transplantation, 1, 3 and 6 months post-transplantation. RESULTS: The levels of IL-2 and STAT had no difference between the induction group and the control group. The level of IL-10 of induction group (59.4 +/- 7.7) ng/L was obviously higher than control group (36.8 +/- 8.4) ng/L at 3 months post-transplantation. CD40L level of induction group (10.6 +/- 3.6) was lower than control group (35.6 +/- 8.4) at 1 month post-transplantation. CONCLUSION: Zenapax can reduce B-cell-mediated humoral immunity at 1 month post-transplantation through CD40L pathway.